



PATENT
Attorney Docket No. 06478.1463-00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
)	
C. Jane ROBINSON et al.)	Group Art Unit: 1651
)	
Application No.: 10/046,278)	Examiner: Susan Marie Hanley
)	
Filed: January 16, 2002)	
)	Confirmation No.: 2377
For: ANTITHROMBIN III FOR)	
DISORDERS CAUSED BY)	
ANGIOGENESIS)	

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(c)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(c), Applicants bring to the attention of the Office the documents on the attached PTO SB/08 form. This Information Disclosure Statement is being filed after the events recited in Section 1.97(b) but, to the undersigned's knowledge, before the mailing date of either a Final action, Quayle action, or a Notice of Allowance. Under the provisions of 37 C.F.R. § 1.97(c), this Information Disclosure Statement is accompanied by a fee of \$180.00 as specified by Section 1.17(p). Copies of the listed documents are attached.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

08/20/2006 SDENB01 00000079 10046278

02 FC:1806

180.00 OP

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Office applies any of the documents as prior art against any claims in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement that is not otherwise enclosed herewith, please charge the fee to Deposit Account No. 06-0916.


Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: August 25, 2006

By: Elizabeth A. Doherty
Elizabeth A. Doherty
Reg. No. 50,894

by
Carol P. Ewald
Reg. No. 32,220



IDS Form PTO/SB/08: Substitute for form 1449A/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			<i>Application Number</i>	10/046,278	
			<i>Filing Date</i>	January 16, 2002	
			<i>First Named Inventor</i>	C. Jane ROBINSON	
			<i>Art Unit</i>	1651	
			<i>Examiner Name</i>	Susan Marie Hanley	
Sheet	1	of	2	<i>Attorney Docket Number</i>	06478.1463-00

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Examiner Initials	Cite No. ¹	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

FOREIGN PATENT DOCUMENTS							
Examiner Initials	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation ⁶
		Country Code ³	Number ⁴ Kind Code ⁵ (if known)				

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation ⁶
		E. ERSDAL-BADJU et al., "Elimination of glycosylation heterogeneity affecting heparin affinity of recombinant human antithrombin III by expression of a β -like variant in baculovirus-infected insect cells," <i>Biochem. J.</i> 310: 323-330 (1995).	
		S. FREBELIUS et al., "Thrombin inhibition by antithrombin III on the subendothelium is explained by the isoform AT β ," <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> 16: 1292-97 (1996).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.